Thu Jan 08 06:28:24 UTC 2026: ### Headline: Bombay High Court Restrains Anrose Pharma from Using “ZEROVOL-P” Trademark

The Story

On January 8, 2026, the Bombay High Court permanently restrained Anrose Pharma from using the trademark ‘ZEROVOL-P’ for pain relief medicines, deeming it “virtually identical” to IPCA Laboratories’ registered trademark ‘ZERODOL’. Justice Arif S. Doctor found Anrose Pharma’s adoption of the mark dishonest and warned of a potential risk of deception within the pharmaceutical trade. Anrose Pharma was directed to pay ₹15 lakh in costs within eight weeks, with an 8% annual interest penalty for non-compliance.

The court emphasized IPCA Laboratories’ established goodwill and distinctiveness with ‘ZERODOL’, which they have been using since 2003. The court also reinforced the stricter standards applied to medicinal products, underscoring the imminent likelihood of confusion if Anrose Pharma continued using the infringing trademark.

Key Points

  • The Bombay High Court ruled against Anrose Pharma in a trademark infringement case.
  • Anrose Pharma was barred from using the trademark ‘ZEROVOL-P’ for pain relief medicines.
  • The court found ‘ZEROVOL-P’ “virtually identical” to IPCA Laboratories’ ‘ZERODOL’ trademark.
  • Anrose Pharma was ordered to pay ₹15 lakh in costs to IPCA Laboratories within eight weeks.
  • IPCA Laboratories has been using the ‘ZERODOL’ trademark since 2003 and has established significant goodwill.

Critical Analysis

There is no applicable context in the provided information to draw an analysis

Key Takeaways

  • Trademark infringement in the pharmaceutical industry is taken seriously by the courts, given the potential for public harm.
  • Established companies with registered trademarks and proven goodwill have a strong legal basis for protecting their intellectual property.
  • Failure to appear in court and defend against a trademark infringement claim can result in significant financial penalties and permanent injunctions.
  • The Commercial Courts Act prioritizes awarding costs to the successful party in such disputes.
  • Stricter scrutiny applies to trademark disputes involving medicinal products due to the heightened risk of public confusion and potential health consequences.

Impact Analysis

There is no applicable context in the provided information to draw an impact analysis

Read More

Related News: